A PYMNTS Company

US: Pay-for-delay lawsuit hits acne medication company

By  |  August 29, 2013

A slew of pharmaceutical companies are facing a lawsuit regarding their alleged delay of the generic form of an acne medication from reaching the shelves, following a recent trend of suits involving pay-for-delay agreements.

A class action lawsuit was filed last Wednesday in federal court in Pennsylvania against makers of the drug, who are accused of harming competition through the delay of the generic form of the drug called Solodyn.

Court documents list Lupin Pharmaceuticals, Impax and other major drug companies as defendants.

The US Supreme Court ruled last June that such pay-for-delay agreements are a valid reason for filing a lawsuit, leading to a new influx of similar lawsuits.

Full Content: The Pennsylvania Record

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.